Oral Estrogen, Thromboembolic Events and Cardiometabolic Risk in Older vs. Younger Transgender Women Veterans
Abstract Data support increases in absolute thromboembolic event (TE) risk and worsening of cardiometabolic (CM) risk factors associated with estrogen (E)-based feminizing gender-affirming hormone therapy (GAHT). Few data exist comparing age, E type and CM risk in transgender women (TW) veterans. We conducted a retrospective analysis in TW prescribed E through our local Veterans Health Administration (VHA) between 2014-2019. Rates of TE (venous and arterial) and CM risk factors (hypertension [HTN], hyperlipidemia [HLD], type 2 diabetes mellitus [T2DM], obesity and smoking) were stratified by age (<45 vs. ≥45 years) and oral vs. never-oral E therapy and compared using Fisher’s Exact Tests. We also compared TW rates with those of local men (N=77,514) and women (N=11,918) veterans using Chi-Square and Fisher’s Exact tests. Of 226 veterans with gender dysphoria, 130 identified as TW and 100 used VHA-prescribed E (<45 years: N=54, ≥45 years: N=46). Only 9 TW (9%) had a history of TE (55.6% venous: 4 deep venous thrombosis +/- pulmonary embolism, 1 superficial thrombophlebitis; 44.4% arterial: 2 myocardial infarction, 2 ischemic stroke). Of the 7 TW with documented age at TE (median: 67 years, range: 33-80) and duration of E prior to TE (median: 5 years, range: 0-22), 4 were on E at the time of TE (2 oral estradiol, 1 conjugated Es, 1 injectable), 2 discontinued E 1-2 years prior to TE, and 1 unknown. Age and HTN were predictors of TE (P<0.01) in univariate logistic regressions. Smoking history, body mass index (BMI) and oral E were not. Odds of TE were 10% higher (95% CI: 2-19%; P<0.05) for every 1-year of any E therapy and 9% higher (95% CI: 3-16%; P<0.01) for every 1-year increase in age at E initiation. TW ≥45 years had higher rates of CM risk including T2DM, 23.9%, HTN, 52.2%, and HLD, 54.3%, than TW <45 years (5.6%, 16.7% and 20.4%, respectively). Obesity rates were similar between age groups (<45 years: 53.7%; ≥45 years: 52.2%). Among TW with oral E, obesity rates were also similar between age groups (<45 years: 54.5%; ≥45 years: 51.4%). Increased levels of LDL-cholesterol, triglycerides, systolic blood pressure (BP), diastolic BP and BMI were observed after any E initiation (P<0.001). These increases remained significant after adjusting for time elapsed between pre-hormone and highest post-hormone values, age at initiation and oral E therapy. In addition, rates of HTN, HLD, obesity and smoking were significantly higher for TW compared to men and women in age-stratified analyses. TW <45 years had a higher rate of T2DM than women (P=0.04) of the same age. TW ≥45 years had higher rates of arterial TE compared to men (p<0.001) and women (P<0.001), and higher rates of venous TE (P=0.02) and T2DM (P=0.01) compared women of the same age. In TW, absolute TE risk was low, but GAHT increased CM risk factors regardless of age and oral E use. Clinicians should consider these findings when discussing risks and benefits of E-based GAHT with TW veterans.